


### Proportion of Samples by Study




## Proportion of Samples by Assay



# Proportion of Samples by Platform





## Proportion of Samples by Cell\_condition



ong2020_T40	Jansky2021_NB12	Verhoeven2022_NB09
ong2020_T44	Jansky2021_NB13	Verhoeven2022_NB11
ong2020_T69	Jansky2021_NB14	Verhoeven2022_NB12
ong2020_T71	Kildisiute2021_10X_PD42752-1	Verhoeven2022_NB13
ong2020_T75	Kildisiute2021_10X_PD42752-2	Verhoeven2022_NB15
ong2020_T92	Kildisiute2021_10X_PD43255	Verhoeven2022_NB16
nsky2021_NB01	Kildisiute2021_10X_PD46693	Verhoeven2022_NB17
nsky2021_NB02	Slyper2020_cell_HTAPP_312_SMP_901	Verhoeven2022_NB18
nsky2021_NB03	Slyper2020_cell_HTAPP_312_SMP_902	Verhoeven2022_NB19
nsky2021_NB04	Slyper2020_cell_HTAPP-656-SMP-3481	Verhoeven2022_NB20
nsky2021_NB05	Slyper2020_nucleus_HTAPP-244-SMP-451_CST	Verhoeven2022_NB21
nsky2021_NB06	Slyper2020_nucleus_HTAPP-244-SMP-451_EZ	Verhoeven2022_NB22
M918/2021_NB07	Slyper2020_nucleus_HTAPP-244-SMP-451_NST	Verhoeven2022_NB23
nsky2021_NB08	Slyper2020_nucleus_HTAPP-244-SMP-451_TST	Verhoeven2022_NB24
nsky2021_NB09	Slyper2020_nucleus_HTAPP-656-SMP-3481_TST	Verhoeven2022_NB26
nsky2021_NB10	Verhoeven2022_NB01	Verhoeven2022_NB34
L 0004 ND44	)/   0000 ND00	\/ I

# Proportion of Samples by Patient\_No






34b

34c


39-T1

39-T2


# Proportion of Samples by Gender




## Proportion of Samples by MYCN\_amplification




# Proportion of Samples by Risk



#### Proportion of Samples by INSS\_stage



#### Proportion of Samples by Timepoint



#### Proportion of Samples by Cell\_type

